Evidence map›Paper›PMID 25035080›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

'Can you look me in the face?' Short-term SSRI administration reverts avoidant ocular face exploration in subjects at risk for psychopathology.

Martina Di Simplicio, Sonia Doallo, Giulia Costoloni, Gustavo Rohenkohl, Anna C Nobre, Catherine J Harmer

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. A neurocognitive model for understanding treatment action in depression.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Martina Di Simplicio1] MRC Cognition and Brain Sciences Unit, Cambridge, UK [2] Department of Psychiatry, University of Oxford, Oxford, UK.
Sonia DoalloDepartment of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Santiago de Compostela, Spain.
Giulia CostoloniNeuroscience Department, Psychiatry Section, University of Siena, Siena, Italy.
Gustavo RohenkohlDepartment of Experimental Psychology and Oxford Centre for Human Brain Activity, University of Oxford, Oxford, UK.
Anna C NobreDepartment of Experimental Psychology and Oxford Centre for Human Brain Activity, University of Oxford, Oxford, UK.
Catherine J HarmerDepartment of Psychiatry, University of Oxford, Oxford, UK.
University of Oxford · GBMRC Cognition and Brain Sciences Unit · GBUniversidade de Santiago de Compostela · ESUniversity of Siena · ITWellcome Centre for Integrative Neuroimaging · GB

Funding

Medical Research Council
6 · The paper itself

Abstract

Anxiety and depression are associated with altered ocular exploration of facial stimuli, which could have a role in the misinterpretation of ambiguous emotional stimuli. However, it is unknown whether a similar pattern is seen in individuals at risk for psychopathology and whether this can be modified by pharmacological interventions used in these disorders. In Study 1, eye gaze movement during face discrimination was compared in volunteers with high vs low neuroticism scores on the Eysenck Personality Questionnaire. Facial stimuli either displayed a neutral, happy, or fearful expression. In Study 2, volunteers with high neuroticism were randomized in a double-blind design to receive the selective serotonin reuptake inhibitor citalopram (20 mg) or placebo for 7 days. On the last day of treatment, eye gaze movement during face presentation and the recognition of different emotional expressions was assessed. In Study 1, highly neurotic volunteers showed reduced eye gaze towards the eyes vs mouth region of the face compared with low neurotic volunteers. In Study 2, citalopram increased gaze maintenance over the face stimuli compared with placebo and enhanced recognition of positive vs negative facial expressions. Longer ocular exploration of happy faces correlated positively with recognition of positive emotions. Individuals at risk for psychopathology presented an avoidant pattern of ocular exploration of faces. Short-term SSRI administration reversed this bias before any mood or anxiety changes. This treatment effect may improve the capacity to scan social stimuli and contribute to the remediation of clinical symptoms related to interpersonal difficulties.

Indexed as

AdultAnalysis of VarianceAntisocial Personality DisorderCitalopramDiscrimination, PsychologicalDouble-Blind MethodEye MovementsFacial ExpressionFemaleHumansMalePersonality InventoryPsychiatric Status Rating ScalesRecognition, PsychologySelective Serotonin Reuptake InhibitorsStatistics as TopicCitalopramSelective Serotonin Reuptake Inhibitors

Identifiers

PMID25035080
PMCPMC4229577
OpenAlexW1999052622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.